Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 3275, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
CPQ Q9Y646 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CPPED1 Q9BRF8 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CPNE6 O95741 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CPNE5 Q9HCH3 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CPNE4 Q96A23 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CPNE4 Q96A23 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CPN2 P22792 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
CPN2 P22792 Xu et al. 2018 ALS Control Plasma Up 42 ALS, 18 control N/A 61.8 ± 9.6 N/A
CPN2 Q96KN2 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
CPN2 P22792 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
CPN1 P15169 Zubiri et al. 2018 ALS fast (early stage) ALS slow (early stage) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CPN1 P15169 Zubiri et al. 2018 Late ALS (ALS fast cohort) Early ALS (ALS fast cohort) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CPN1 P15169 Zubiri et al. 2018 Late ALS (ALS slow cohort) Early ALS (ALS slow cohort) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CPN1 P15169 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
CPLX1 O14810 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CPLX1 D6RI11 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CPE P16870 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
CPB2 Q96IY4 Zubiri et al. 2018 ALS fast (early stage) ALS slow (early stage) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CPB2 Q96IY4 Zubiri et al. 2018 Late ALS (ALS fast cohort) Early ALS (ALS fast cohort) Plasma Up 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CPB2 A0A087WSY5 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CPB2 Q96IY4 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
CPB1 P15086 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CPAMD8 Q8IZJ3 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CP P00450 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CP P00450 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CP P00450 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
COX6C P09669 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
COX6C P09669 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
COX6B1 P14854 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
COX6B1 P14854 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
COX6B1 P14854 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
COX6B1 P14854 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
COX6A1 P12074 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
COX5B P10606 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
COX5B P10606 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
COX5B P10606 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
COX5A P20674 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
COX5A P20674 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
COX4I1 P13073 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
COTL1 Q14019 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COTL1 Q14019 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
COTL1 Q14019 Zhou et al. 2023 BO-ALS SO-ALS CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CORO2A Q92828 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CORO1C Q9ULV4 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CORO1C Q9ULV4 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CORO1A P31146 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
COR1C Q9ULV4 Andrés-Benito et al. 2020 ALS Control CSF Down 15 ALS, 15 control N/A 61 ± 10.8 N/A
COPS4 Q9BT78 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
COPS3 J3QKR0 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
COPB2 P35606 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
COPA P53621 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
COPA P53621 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
COMT P21964 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
COMP P49747 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
COMP P49747 Katzeff et al. 2020 ALS Control Serum Down 28 ALS, 22 control N/A 52.7 N/A
COMP P49747 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL8A1 P27658 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
COL6A3 P12111 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL6A2 P12110 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL5A2 P05997 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL4A2 P08572 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL4A2 P08572 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
COL28A1 Q2UY09 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL21A1 Q96P44 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL1A1 P02452 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
COL18A1 P39060 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL16A1 Q07092 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL15A1 P39059 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
COL14A1 Q05707 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
COL11 Q9BWP8 Vilardo et al. 2024 ALS (validation cohort) ALS (validation cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
COA3 Q9Y2R0 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CO9 P02748 Vilardo et al. 2024 ALS (validation cohort) ALS (validation cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
CO9 P02748 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
CO5 P01031 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
CO3 P01024 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
CNTNAP5 Q8WYK1 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CNTNAP4 Q9C0A0 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CNTNAP3 Q9BZ76 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CNTNAP2 Q9UHC6 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CNTNAP1 P78357 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CNTN2 Q02246 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
CNRIP1 Q96F85 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CNPY4 Q8N129 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CNP P09543 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CNN3 Q15417 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CNN3 Q15417 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CNKSR2 Q8WXI2 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CNDP2 Q96KP4 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CNDP2 Q96KP4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CNDP1 Q96KN2 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CLVS2 Q5SYC1 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CLUL1 Q15846 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CLU P10909 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CLTB P09497 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CLTB P09497 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
CLTA P09496 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CLTA P09496 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CLSTN1 O94985 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CLSTN1 O94985 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
CLPTM1 O96005 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2